107 related articles for article (PubMed ID: 23962442)
1. Regulation of intraocular pressure in mice: structural analysis of dopaminergic and serotonergic systems in response to cabergoline.
Platania CB; Leggio GM; Drago F; Salomone S; Bucolo C
Biochem Pharmacol; 2013 Nov; 86(9):1347-56. PubMed ID: 23962442
[TBL] [Abstract][Full Text] [Related]
2. Cabergoline: Pharmacology, ocular hypotensive studies in multiple species, and aqueous humor dynamic modulation in the Cynomolgus monkey eyes.
Sharif NA; McLaughlin MA; Kelly CR; Katoli P; Drace C; Husain S; Crosson C; Toris C; Zhan GL; Camras C
Exp Eye Res; 2009 Mar; 88(3):386-97. PubMed ID: 18992242
[TBL] [Abstract][Full Text] [Related]
3. Dopamine-₃ receptor modulates intraocular pressure: implications for glaucoma.
Bucolo C; Leggio GM; Maltese A; Castorina A; D'Agata V; Drago F
Biochem Pharmacol; 2012 Mar; 83(5):680-6. PubMed ID: 22178719
[TBL] [Abstract][Full Text] [Related]
4. Serotonin-2 receptor agonists as novel ocular hypotensive agents and their cellular and molecular mechanisms of action.
Sharif NA
Curr Drug Targets; 2010 Aug; 11(8):978-93. PubMed ID: 20426763
[TBL] [Abstract][Full Text] [Related]
5. The bulky N6 substituent of cabergoline is responsible for agonism of this drug at 5-hydroxytryptamine 5-HT2A and 5-HT2B receptors and thus is a determinant of valvular heart disease.
Kekewska A; Hübner H; Gmeiner P; Pertz HH
J Pharmacol Exp Ther; 2011 Jul; 338(1):381-91. PubMed ID: 21518772
[TBL] [Abstract][Full Text] [Related]
6. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: I. Cellular, electrophysiological, and neurochemical profile in comparison with ropinirole.
Millan MJ; Cussac D; Gobert A; Lejeune F; Rivet JM; Mannoury La Cour C; Newman-Tancredi A; Peglion JL
J Pharmacol Exp Ther; 2004 Jun; 309(3):903-20. PubMed ID: 14978194
[TBL] [Abstract][Full Text] [Related]
7. Molecular modeling and docking studies of human 5-hydroxytryptamine 2A (5-HT2A) receptor for the identification of hotspots for ligand binding.
Kanagarajadurai K; Malini M; Bhattacharya A; Panicker MM; Sowdhamini R
Mol Biosyst; 2009 Dec; 5(12):1877-88. PubMed ID: 19763327
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the ocular hypotensive response of serotonin 5-HT1A and 5-HT2 receptor ligands in conscious ocular hypertensive cynomolgus monkeys.
May JA; McLaughlin MA; Sharif NA; Hellberg MR; Dean TR
J Pharmacol Exp Ther; 2003 Jul; 306(1):301-9. PubMed ID: 12676887
[TBL] [Abstract][Full Text] [Related]
9. Identification of structural determinants of ligand selectivity in 5-HT₂ receptor subtypes on the basis of protein-ligand interactions.
Jang JW; Kim MS; Cho YS; Cho AE; Pae AN
J Mol Graph Model; 2012 Sep; 38():342-53. PubMed ID: 23085173
[TBL] [Abstract][Full Text] [Related]
10. Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors: design, synthesis, and effects on behavior.
Butini S; Gemma S; Campiani G; Franceschini S; Trotta F; Borriello M; Ceres N; Ros S; Coccone SS; Bernetti M; De Angelis M; Brindisi M; Nacci V; Fiorini I; Novellino E; Cagnotto A; Mennini T; Sandager-Nielsen K; Andreasen JT; Scheel-Kruger J; Mikkelsen JD; Fattorusso C
J Med Chem; 2009 Jan; 52(1):151-69. PubMed ID: 19072656
[TBL] [Abstract][Full Text] [Related]
11. Beta-oxygenated analogues of the 5-HT2A serotonin receptor agonist 1-(4-bromo-2,5-dimethoxyphenyl)-2-aminopropane.
Glennon RA; Bondarev ML; Khorana N; Young R; May JA; Hellberg MR; McLaughlin MA; Sharif NA
J Med Chem; 2004 Nov; 47(24):6034-41. PubMed ID: 15537358
[TBL] [Abstract][Full Text] [Related]
12. Serotonin 1A and 2A receptor densities, neurochemical and behavioural characteristics in two closely related mice strains after long-term isolation.
Schiller L; Donix M; Jähkel M; Oehler J
Prog Neuropsychopharmacol Biol Psychiatry; 2006 May; 30(3):492-503. PubMed ID: 16412547
[TBL] [Abstract][Full Text] [Related]
13. In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist.
Glennon JC; Van Scharrenburg G; Ronken E; Hesselink MB; Reinders JH; Van Der Neut M; Long SK; Feenstra RW; McCreary AC
Synapse; 2006 Dec; 60(8):599-608. PubMed ID: 17001660
[TBL] [Abstract][Full Text] [Related]
14. Agonism at 5-HT2B receptors is not a class effect of the ergolines.
Jähnichen S; Horowski R; Pertz HH
Eur J Pharmacol; 2005 Apr; 513(3):225-8. PubMed ID: 15862804
[TBL] [Abstract][Full Text] [Related]
15. Effects of prostanoid EP agonists on mouse intraocular pressure.
Saeki T; Ota T; Aihara M; Araie M
Invest Ophthalmol Vis Sci; 2009 May; 50(5):2201-8. PubMed ID: 19117925
[TBL] [Abstract][Full Text] [Related]
16. Asymmetric total synthesis and identification of tetrahydroprotoberberine derivatives as new antipsychotic agents possessing a dopamine D(1), D(2) and serotonin 5-HT(1A) multi-action profile.
Sun H; Zhu L; Yang H; Qian W; Guo L; Zhou S; Gao B; Li Z; Zhou Y; Jiang H; Chen K; Zhen X; Liu H
Bioorg Med Chem; 2013 Feb; 21(4):856-68. PubMed ID: 23332346
[TBL] [Abstract][Full Text] [Related]
17. X-ray crystal structure and conformational analysis of N-(3-dimethylaminopropyl)-N-(ethylaminocarbonyl)-6-(2-propenyl)er goline -8 beta-carboxamide (Cabergoline): comparison with bromocriptine and lisuride and a hypothesis for its high dopaminergic activity.
Sabatino P; Riva di Sanseverino L; Tonani R
Farmaco; 1995 Mar; 50(3):175-8. PubMed ID: 7755864
[TBL] [Abstract][Full Text] [Related]
18. The effect of the H-1152P, a potent Rho-associated coiled coil-formed protein kinase inhibitor, in rabbit normal and ocular hypertensive eyes.
Nishio M; Fukunaga T; Sugimoto M; Ikesugi K; Sumi K; Hidaka H; Uji Y
Curr Eye Res; 2009 Apr; 34(4):282-6. PubMed ID: 19373576
[TBL] [Abstract][Full Text] [Related]
19. An in vivo pharmacological evaluation of pardoprunox (SLV308)--a novel combined dopamine D(2)/D(3) receptor partial agonist and 5-HT(1A) receptor agonist with efficacy in experimental models of Parkinson's disease.
Jones CA; Johnston LC; Jackson MJ; Smith LA; van Scharrenburg G; Rose S; Jenner PG; McCreary AC
Eur Neuropsychopharmacol; 2010 Aug; 20(8):582-93. PubMed ID: 20434890
[TBL] [Abstract][Full Text] [Related]
20. Proterguride, a highly potent dopamine receptor agonist promising for transdermal administration in Parkinson's disease: interactions with alpha(1)-, 5-HT(2)- and H(1)-receptors.
Schurad B; Horowski R; Jähnichen S; Görnemann T; Tack J; Pertz HH
Life Sci; 2006 Apr; 78(20):2358-64. PubMed ID: 16310806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
